UBE2G1 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 4.85167461761193E-13 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.41030000000431E-06 |
Normal-vs-Stage2 |
1.025060E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.355090E-03 |
Stage1-vs-Stage2 |
3.732400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
1.810440E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
5.615400E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
6.28475049779809E-12 |
Normal-vs-AfricanAmerican |
5.224300E-02 |
Normal-vs-Asian |
1.221760E-01 |
Caucasian-vs-AfricanAmerican |
2.380700E-03 |
Caucasian-vs-Asian |
7.928800E-01 |
AfricanAmerican-vs-Asian |
6.502000E-02 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
2.47190000002284E-06 |
Normal-vs-Female |
6.63439999604165E-08 |
Male-vs-Female |
5.349800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.139640E-03 |
Normal-vs-Extreme_Weight |
2.04810000004052E-06 |
Normal-vs-Obese |
6.791300E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
7.615600E-01 |
Normal_Weight-vs-Obese |
1.058600E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
1.034210E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.158380E-01 |
Normal-vs-Age(41-60Yrs) |
3.604600E-04 |
Normal-vs-Age(61-80Yrs) |
3.84730000080324E-08 |
Normal-vs-Age(81-100Yrs) |
2.129800E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.527400E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.516600E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.017600E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.302000E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.428000E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.706200E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
4.383800E-01 |
Normal-vs-Grade 3 |
6.085400E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
4.552800E-01 |
Grade 2-vs-Grade 4 |
4.383800E-01 |
Grade 3-vs-Grade 4 |
6.085400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
4.40180003558055E-09 |
Normal-vs-N1 |
1.185850E-02 |
N0-vs-N1 |
7.351800E-02 |
|
|